Amicus Therapeutics, Inc. (FOLD)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

The chart shows the growth of an initial investment of $10,000 in Amicus Therapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.

Amicus Therapeutics, Inc. (FOLD) has returned 1.54% so far this year and 77.21% over the past 12 months. Over the last ten years, FOLD has returned 5.22% per year, falling short of the S&P 500 Index benchmark, which averaged 12.16% annually.

Based on dividend-adjusted daily data since May 31, 2007, FOLD's average daily return is +0.09%, while the average monthly return is +1.74%. At this rate, your investment would double in approximately 3.3 years.

Historically, 50% of months were positive and 50% were negative. The best month was Jan 2012 with a return of +89.0%, while the worst month was Oct 2009 at -56.1%. The longest winning streak lasted 11 consecutive months, and the longest losing streak was 7 months.

On a daily basis, FOLD closed higher 50% of trading days. The best single day was Mar 19, 2015 with a return of +33.3%, while the worst single day was Oct 2, 2015 at -53.5%.

Amicus Therapeutics, Inc. has an annualized alpha of 12.09%, beta of 1.18, and R² of 0.12 versus S&P 500 Index. Calculated based on daily prices since June 01, 2007.

• This stock participated in 122.81% of S&P 500 Index downside but only 89.48% of its upside — more exposed to losses than it benefited from rallies.
• R² of 0.12 means this stock moves largely independently of S&P 500 Index — capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

FOLD ranks 84 for risk / return — in the top 84% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.

The table below present risk-adjusted performance metrics for Amicus Therapeutics, Inc. (FOLD) and compare them to a chosen benchmark (S&P 500 Index).

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Amicus Therapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Amicus Therapeutics, Inc. was 89.91%, occurring on Apr 16, 2014. Recovery took 328 trading sessions.

The current Amicus Therapeutics, Inc. drawdown is 41.90%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Amicus Therapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Amicus Therapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.